Bone metastasis

Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio

Retrieved on: 
Thursday, October 12, 2023
Pharmaceutical, Health, Oncology, Partnership, Senior, NYSE, Good manufacturing practice, Public, Bone pain, Bevacizumab, Bone, Cancer, Denosumab, Fracture, GMP, Bone metastasis, Medication, Patient, Global health, Generic drug

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia® and XGEVA® to its biosimilar pipeline.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia® and XGEVA® to its biosimilar pipeline.
  • The two denosumab products are being developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals.
  • “Our first three commercial U.S. biosimilars are doing very well as our excellent commercial team drives uptake in these competitive categories.
  • The financial terms of the transaction were not disclosed, and any incremental expenses associated with these products are contemplated within Amneal’s guidance.

QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data

Retrieved on: 
Wednesday, August 16, 2023
CT, Radiation, Bone, Neoplasm, PSMA, PSMA5, Bone metastasis, Survival, RECIST, Cancer, OTCQB, Spine, Breast, Prostate, Radiopharmaceutical, Lung, Incidence, Patient, Physician, Prostate cancer, Diagnosis, QSAM, Lung cancer, FDA, Letter, Ecosystem, Environment, Social media, Safety, Breast cancer, Medical imaging, Pharmaceutical industry, Female, SUV, Q4

In patients one and three, we saw no progression of tumor size at the four month follow-up.

Key Points: 
  • In patients one and three, we saw no progression of tumor size at the four month follow-up.
  • We must remind our shareholders, however, that these results are very early and are not necessarily indicative of future results in our trials.
  • Further, this summary is not a formal read-out of data, but rather, a preliminary analysis of our Cohort 1 findings.
  • Ultimately, however, our primary mission is to help the hundreds of thousands of adults and children each year suffering from bone cancer.

New Drug Shows Promise in Treating Bone Metastasis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 31, 2023
General Health, Pharmaceutical, Health, Oncology, KOL, Therapy, PESTLE, Bone metastasis, Internet, Epidemiology, Intelligence, Research, SWOT, Growth–share matrix, Porter's five forces analysis, United Kingdom, Diagnosis, News, Treatment, Disease, SME, Pharmaceutical industry, Medical imaging

The report provides a comprehensive analysis of the bone metastasis market, including epidemiology, treatment practices, and emerging drugs.

Key Points: 
  • The report provides a comprehensive analysis of the bone metastasis market, including epidemiology, treatment practices, and emerging drugs.
  • Bone Metastasis Epidemiology: The epidemiology section offers insights into the historical and current patient pool of bone metastasis in the seven major countries.
  • Bone Metastasis Drugs: The report includes an analysis of both marketed drugs and late-stage pipeline drugs for bone metastasis.
  • Bone Metastasis Drugs Uptake: The report focuses on the rate of uptake of potential drugs recently launched or expected to be launched in the bone metastasis market between 2019 and 2032.

HR Positive/ Her2 Negative Breast Cancer - Pipeline Insight, 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 22, 2023
Health, Oncology, CISH, Sequela, Triple-negative breast cancer, FISH, Therapy, Cleavage, HER2, CDK, Bone metastasis, Survival, Clinical trial, Route of administration, Quality of life, Lead, Woman, ERBB2, AstraZeneca, Rated R, IHC, II, Sapporo Medical University, Combination therapy, Route, Daiichi Sankyo, Administration, US, Discovery, ET, Patient, Breast cancer, Risk, DXD, Immunoglobulin G, HR, In situ hybridization, Immunohistochemistry, ADC, Growth, Mortality, Spacecraft, Lymph node, Recurrence, News, III, SERD, DFS, Birth control, Medical imaging, Pharmaceutical industry, Dietary supplement, Fine chemical

This "HR Positive/ HER2 Negative Breast Cancer - Pipeline Insight, 2023" report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape.

Key Points: 
  • This "HR Positive/ HER2 Negative Breast Cancer - Pipeline Insight, 2023" report provides comprehensive insights about 50+ companies and 53+ pipeline drugs in HR Positive/ HER2 Negative Breast Cancer pipeline landscape.
  • Depending on the levels of HER2 or ERBB2 in the laboratory test breast cancer is classified as HER2 or ERBB2 positive or HER2 negative breast cancer.
  • A detailed picture of the HR Positive/ HER2 Negative Breast Cancer pipeline landscape is provided which includes the disease overview and HR Positive/ HER2 Negative Breast Cancer treatment guidelines.
  • HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

Retrieved on: 
Wednesday, March 8, 2023
QSAM, Surveillance, Bone metastasis, Label, Protocol, Oncology, OTCQB, FDA, Safety, Prostate cancer, Metastasis, Collection, Clinical trial, Breast cancer, Internal medicine, Cancer, Patient, Prevalence, Bone, NIH, Pharmaceutical industry, Medical imaging, Epidemiology

This amendment to the enrollment criteria significantly expands the population of potential participants in QSAM’s Phase 1 study evaluating CycloSam® in the treatment of bone cancer.

Key Points: 
  • This amendment to the enrollment criteria significantly expands the population of potential participants in QSAM’s Phase 1 study evaluating CycloSam® in the treatment of bone cancer.
  • The prevalence of bone metastases in patients over age 70 is greater than 30% among breast cancer patients and almost 50% for prostate cancer patients, according to recently published literature from the NIH SEER database (Surveillance, Epidemiology, and End Results).
  • Older patients comprise a significant percentage of the current population of patients with metastatic bone cancer that is targeted by the CycloSam® drug product.
  • Our mission at QSAM is making sure the broadest possible population fighting this deadly disease may one day be able to benefit from CycloSam®.”

Global Bone Cancer Diagnosis and Therapeutics Market Report 2022: R&D and Technological Advancements & New Product Launches to Bolster Growth - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023
Biotechnology, Health, Oncology, Medical Devices, News, Paget's disease, Bayer, Novartis, R, Therapy, Multiple myeloma, Diagnosis, Health, Ewing's sarcoma, Amgen, Denosumab, Growth, Patient, Transplant, Cancer, BeiGene, Pfizer, Merck & Co., Bone metastasis, Chondrosarcoma, Acquisition, Bone, Medical device, Agriculture, Pharmaceutical industry, Medical imaging, Marketing, Osteosarcoma

The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.
  • New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market.
  • Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others.

Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Health, Pharmaceutical, Bone metastasis, Pancreatic cancer, Lyman-alpha emitter, Ovarian cancer, Growth, Pet

The "Alpha Emitters: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alpha Emitters: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
  • Bone Metastasis, one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$888.5 Million by the end of the analysis period.
  • Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 21.8% CAGR for the next 7-year period.
  • In the global Pancreatic Cancer segment, USA, Canada, Japan, China and Europe will drive the 21.2% CAGR estimated for this segment.

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

Retrieved on: 
Monday, June 13, 2022
Oncology, Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Osteoporosis, Docetaxel, R, Multiple myeloma, GMP, Bone, Mesothelioma, Trastuzumab, Hepatocellular carcinoma, Review, NYSE, COVID-19, Denosumab, U.S. Securities and Exchange Commission, Degenerative disease, Neutralizing antibody, Renal cell carcinoma, Forward-looking statement, CEO, HER2, MSI, Health, Esophageal cancer, NDA, Osteosarcoma, Bevacizumab, Pertuzumab, Bone metastasis, Patent, Annual report, Security (finance), Ipilimumab, Fracture, Patient, Squamous cell carcinoma, SEC, IgG4-related ophthalmic disease, Colorectal cancer, Adalimumab, Woman, Achievement, Mab, OGN, Breast cancer, Investment, NMPA, Growth, Private Securities Litigation Reform Act, Rituximab, Medical imaging, Fine chemical, Pharmaceutical industry, Organon

Organon (NYSE: OGN), a global womens health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai Henlius Biotech, Inc. (2696.HK), whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab, HLX11) and Prolia/Xgeva (denosumab, HLX14).

Key Points: 
  • Organon (NYSE: OGN), a global womens health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai Henlius Biotech, Inc. (2696.HK), whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab, HLX11) and Prolia/Xgeva (denosumab, HLX14).
  • Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan.
  • The agreement also includes an option to negotiate an exclusive license for global commercialization rights for a biosimilar candidate referencing Yervoy (ipilimumab, HLX13).
  • HLX11 (anti-HER2 domain II humanized monoclonal antibody injection) is a biosimilar candidate of pertuzumab and is independently developed by Henlius.

Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia® and Xgeva®

Retrieved on: 
Thursday, December 9, 2021
Osteoporosis, Food, Patient, Osteoclast, Cancer, Partnership, Osteosarcoma, Bone metastasis, Bone, RANKL, Fracture, Bone loss, Hikma, Gideon, China Biologic Products, Scott Richter, Cell, Richter, US Foods, Fine chemical, Pharmaceutical industry, Health insurance

("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").

Key Points: 
  • ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia and Xgeva("Products"), in the United States ("US").
  • Hikma is responsible for registering the Products with the US Food and Drug Administration and will have exclusive rights to commercialise them in the US.
  • "We are looking forward to collaborating with Hikma on this important biosimilar project targeting the US market," said Gbor Orbn, Chief Executive Officer of Richter.
  • Denosumab is a RANKL inhibitor which works by preventing the development of osteoclasts, which are cells that break down bone.

Global Nuclear Medicine Markets, Forecast & Opportunities Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 23, 2021
General Health, Health, Oncology, Other Health, Adoption, Forecast, Application, Therapy, Cancer, Patient, Biomarker, Nuclear medicine, Isotopes of molybdenum, Y-90, Lymphoma, F-18, Radiopharmaceutical, Prevalence, Disease, Bone metastasis, Research, Radiation, Incidence, Molecular imaging, X-ray, Medical imaging

The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains.
  • The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region.
  • Based on type, the nuclear medicine market is segmented into Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes.